Sermorelin injections are subcutaneous: the medication goes into the fatty layer beneath the skin, not into muscle. They are commonly scheduled near bedtime because sermorelin mimics growth hormone-releasing hormone (GHRH), the hypothalamic signal that prompts the pituitary to release growth hormone. A prescription should specify the amount, timing, injection sites, and storage for the exact formulation dispensed.
That makes the practical experience less dramatic than online protocols suggest. It is a small injection followed by an ordinary night, not a shot that produces an immediate, reliable sensation.
What a sermorelin injection does
Sermorelin is a synthetic version of the first 29 amino acids of human GHRH. It acts upstream of growth hormone: it signals a responsive pituitary rather than supplying growth hormone directly. That distinction matters because a sermorelin injection still depends on the body's own endocrine pathway.
The clearest direct treatment evidence comes from an older population unlike most adults seeking sermorelin today. In a 1996 open-label study, 110 children with growth hormone deficiency received GHRH-(1-29) by subcutaneous injection at bedtime; investigators evaluated growth and safety at three- to six-month intervals (Thorner et al., Journal of Clinical Endocrinology & Metabolism, 1996). It confirms the route and historical bedtime protocol. It does not establish a first-week benefit timeline for adults.
For the amount itself, sermorelin dosage decisions belong with the prescriber. The concentration of a compounded vial changes how a prescribed amount maps to syringe markings, so copying someone else's number can produce the wrong dose.
Why sermorelin injections are often timed at bedtime
Growth hormone secretion is pulsatile rather than steady, and its largest daily pulse is closely linked to early deep sleep. In a human physiology study that sampled six young men every 30 seconds overnight, growth hormone secretory rates were highest during stages 3 and 4; maximal release occurred within minutes of entering those stages (Holl et al., Journal of Clinical Endocrinology & Metabolism, 1991).
That physiology explains the common bedtime timing: the GHRH-like signal is placed near the sleep-onset growth hormone pulse. It does not mean every prescription uses the same clock time or frequency. Shift work, sleep timing, other medications, and the formulation can all affect the plan, and the prescriber sets the actual schedule.
Sermorelin injection sites and rotation
Common subcutaneous areas include the abdomen, front of the thigh, and outer upper arm. The prescription materials should identify which sites are appropriate for the supplied formulation and how the clinician wants them rotated. Areas that are bruised, scarred, irritated, or already tender are poor choices unless a clinician has specifically said otherwise.
Rotation means moving to a fresh point rather than repeatedly using one comfortable spot. It gives local tissue time to recover and makes it easier to tell whether redness, swelling, or tenderness is isolated or recurring. A small written site log can help, but it should contain only location and date—not dose changes made without the prescriber.
The first few weeks are often more about learning that routine than observing a clear therapeutic effect. Brief local pain, redness, or swelling were the most common treatment-related events in historical Geref pediatric trials, occurring in about 16% of patients according to an FDA medical review. That number comes from children using the former branded product, so it should not be treated as a rate for today's compounded adult formulations. Persistent reactions, hives, facial swelling, or breathing trouble warrant prompt medical advice.
Where CJC-1295 and ipamorelin fit
CJC-1295 is another GHRH analog, while ipamorelin signals through a different growth-hormone secretagogue pathway. A combined CJC-1295/ipamorelin prescription is therefore an alternative clinical approach, not a stronger version of sermorelin or an automatic add-on. The compounds have different pharmacology and should not be swapped on the basis of matching syringe volume.
What to expect in the first weeks
There is no well-supported adult timetable in which sleep, recovery, body composition, or energy predictably changes by a particular week. Not feeling something immediately does not prove the injection failed, and feeling different does not prove sermorelin caused it. The useful early observations are more concrete: whether the routine is manageable, whether injection sites remain comfortable, and whether anything new should be reported to the reviewing clinician.
The evidence on whether sermorelin works deserves its own careful answer. Here, the practical point is that historical outcomes were evaluated over months and in specific clinical populations. Expectations from those studies cannot simply be transferred to a modern compounded prescription for an adult.
Sermorelin also is not the same intervention as injecting somatropin. Sermorelin versus HGH explains why prompting pituitary release and supplying growth hormone directly create different clinical questions.
Storage depends on the dispensed formulation
Compounded preparations can differ in concentration, diluent, packaging, beyond-use date, and storage requirements. The pharmacy label is the controlling instruction. Some products require refrigeration after mixing; others may arrive as a ready-to-use solution with different directions. Do not infer the rule from another vial or from the former Geref product.
Keep the vial protected as directed, check the label's beyond-use date, and contact the dispensing pharmacy if it was left outside its stated temperature range, frozen unexpectedly, or looks cloudy or particulate. How to store peptides covers the handling questions to ask without substituting for the label on a specific prescription.
Current status and a clinically accountable route
As of September 2026, no FDA-approved sermorelin product is currently marketed; the compounded formulation offered here is not FDA-approved. The FDA's 2026 Orange Book lists Geref in its discontinued drug product section. FDA withdrew the two Geref approvals effective June 18, 2009, after the manufacturer discontinued the products, and later determined that they were not withdrawn for safety or effectiveness reasons (Federal Register, 2013).
A licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision belongs to the patient and prescriber. The practical difference from a grey-market vial is accountability for the prescription, dispensing record, instructions, and follow-up.
Before the first injection
The prescription should answer four questions before use: the exact amount, the intended timing, the approved sites for that formulation, and its storage after opening or mixing. It should also explain whom to contact after a missed dose or a reaction. Reconstitution is a separate skill and should be demonstrated from the supplied materials, not reverse-engineered from a video.
At Promise, a licensed provider reviews every request and prescribes only when sermorelin is medically appropriate. Not everyone qualifies.